Does OPKO Health disclose any related-party transactions with Subbarao Uppaluri?

No. OPKO Health states that since the beginning of its last fiscal year, it has not engaged in any transaction with Subbarao Uppaluri involving a direct or indirect material interest that would require disclosure under Item 404(a) of Regulation S-K.

OPKO Health (OPK) appoints former CFO Subbarao Uppaluri to board

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

OPKO Health, Inc. has appointed Subbarao V. Uppaluri, Ph.D. as a new independent director, effective March 18, 2026. He will serve until the 2026 Annual Meeting of Stockholders and is expected to join the Compensation Committee.

Dr. Uppaluri previously served as OPKO’s Senior Vice President and Chief Financial Officer from 2007 to 2012 and later as a consultant. The board cites his independence under SEC and Nasdaq rules and notes there are no related-party transactions requiring disclosure. He fills a vacancy created by the passing of longtime director Dr. Richard Krasno and will receive the company’s standard non-employee director compensation and indemnification protections.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

03/19/2026 - 04:50 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): March 18, 2026

    

OPKO Health, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-33528	75-2402409
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4400 Biscayne Blvd.
Miami, Florida		33137
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 305 575-4100

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	OPK	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 18, 2026, the Board of Directors of OPKO Health, Inc. (the “Company”), appointed Subbarao V. Uppaluri, Ph.D. as a new director with immediate effect to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor shall be duly elected or appointed or his earlier death or resignation. Dr. Uppaluri is expected to be appointed to the Compensation Committee of the Board. There is no arrangement or understanding between Dr. Uppaluri and any other persons pursuant to which Dr. Uppaluri was selected as a director. The Board has determined that Dr. Uppaluri is independent under the applicable rules of the Securities and Exchange Commission and the Nasdaq Stock Market.

Dr. Uppaluri served as Senior Vice President and Chief Financial Officer of the Company from May 2007 until his retirement in July 2012 and as a consultant of the Company until February 2014. He served as the Vice President, Strategic Planning and Treasurer of IVAX from 1997 until December 2006. Dr. Uppaluri served in various positions, including Senior Vice President, Senior Financial Officer, Chief Investment Officer, and Controller with several publicly traded banks and began his career in engineering, marketing and research positions with multinational companies and research institutes in India and the United States. Dr. Uppaluri currently serves on the board of Baptist Health Homestead Hospital. Dr. Uppaluri previously served on the boards of Non-Invasive Monitoring Systems, Inc. from 2008 until 2025 and several other publicly traded companies.

Since the beginning of the Company’s last fiscal year, the Company has not engaged in any transaction, or any currently proposed transaction, in which Dr. Uppaluri had or will have a direct or indirect material interest that would require disclosure pursuant to Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission.

Dr. Uppaluri will participate in the standard non-employee director compensation arrangements described in the section entitled “Director Compensation” that is included in the Company’s 2025 Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 14, 2025. The Company has also entered into its standard director indemnification agreement with Dr. Uppaluri, a form of which has been filed or incorporated by reference as Exhibit 10.3 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 2, 2020.

Dr. Uppaluri was appointed to the Board of Directors due to a vacancy as a result of the passing of Dr. Richard Krasno who served on the Company’s Board of Directors beginning in February 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			OPKO Health, Inc.

Date:	March 19, 2026	By:	/s/ Steven D. Rubin
		Name:	Steven D. Rubin
		Title:	Executive Vice President - Administration

Source: View Original Filing on SEC EDGAR

FAQ

What did OPKO Health (OPK) announce regarding its board of directors?

OPKO Health appointed Subbarao V. Uppaluri, Ph.D. as a new independent director effective March 18, 2026. He will serve until the 2026 Annual Meeting of Stockholders and is expected to join the board’s Compensation Committee.

Who is Subbarao V. Uppaluri, the new OPKO Health (OPK) director?

Subbarao V. Uppaluri, Ph.D. is a former OPKO Senior Vice President and Chief Financial Officer who served from 2007 to 2012. He has extensive prior experience in finance and strategic planning roles at IVAX and several publicly traded banks.

Is the new OPKO Health (OPK) director considered independent?

Yes, OPKO’s board determined that Subbarao V. Uppaluri is independent under applicable Securities and Exchange Commission and Nasdaq Stock Market rules. The company also states there are no related-party transactions involving him that require disclosure under Item 404(a) of Regulation S-K.

Why was Subbarao V. Uppaluri appointed to OPKO Health’s board?

He was appointed to fill a vacancy created by the passing of director Dr. Richard Krasno, who served on OPKO’s board since 2017. The appointment adds financial and strategic expertise, supported by Uppaluri’s prior CFO and banking background.

What compensation will the new OPKO Health (OPK) director receive?

Subbarao V. Uppaluri will participate in OPKO’s standard non-employee director compensation program described in its 2025 proxy statement. The company also entered into its standard director indemnification agreement with him, previously filed with its 2019 annual report.

Filing Exhibits & Attachments

1 document